《大行報告》大摩:1月長線投資者繼續增持中國ADRs 對沖基金轉而增持A股
大摩發表報告指,1月長線投資者繼續增持中國ADRs。該行資金流向分析顯示,1月至今,美國的長線基金經理淨買入13億美元的中國ADRs,是連續第二個月出現淨流入,而且流入量是自2021年以來最強勁。
該行指,跡象顯示美國投資者正在增加對中國投資的再平衡。1月至今,拼多多(PDD.US)、百度(BIDU.US)、攜程(TCOM.US)和蔚來(NIO.US)在大型股中被買入最多,而唯品會(VIPS.US)、嗶哩嗶哩(BILI.US)和新東方教育(EDU.US)在大盤股中的資金流入量最大。
不過,1月對沖基金就一直減持中國ADRs,並轉而增持A股。該行認為對沖基金對內地市場情緒看法仍然穩定,但傾向於認為A股可能趕上離岸股票表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.